ACCESSWIRE
01 Oct 2022, 02:37 GMT+10
NEW YORK, NY / ACCESSWIRE / September 30, 2022 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
HGEN Shareholders Click Here: https://www.zlk.com/pslra-1/humanigen-inc-lawsuit-submission-form?prid=32300&wire=1
ABT Shareholders Click Here: https://www.zlk.com/pslra-1/abbott-laboratories-class-action-lawsuit-submission-form?prid=32300&wire=1
FLGT Shareholders Click Here: https://www.zlk.com/pslra-1/fulgent-genetics-lawsuit-loss-submission-form?prid=32300&wire=1
* ADDITIONAL INFORMATION BELOW *
Humanigen, Inc. (NASDAQ:HGEN)
HGEN Lawsuit on behalf of: investors who purchased May 28, 2021 - July 12, 2022
Lead Plaintiff Deadline : October 25, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/humanigen-inc-lawsuit-submission-form?prid=32300&wire=1
According to the filed complaint, during the class period, Humanigen, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Humanigen's lead product candidate, lenzilumab, was less effective in treating hospitalized COVID-19 patients than defendants had represented; (ii) as a result, the U.S. Food and Drug Administration was unlikely to approve the lenzilumab Emergency Use Authorization and the ACTIV-5/BET-B study was unlikely to meet its primary endpoint; (iii) accordingly, lenzilumab's clinical and commercial prospects were overstated; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Abbott Laboratories (NYSE:ABT)
This lawsuit is on behalf of all persons or entities who purchased or otherwise acquired shares of Abbott common stock during the period from February 19, 2021, to June 8, 2022, inclusive.
Lead Plaintiff Deadline : October 31, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/abbott-laboratories-class-action-lawsuit-submission-form?prid=32300&wire=1
According to the filed complaint, defendants touted the strength of Abbott's infant formula brands and their contribution to the Company's sales and revenue growth, despite knowing that the facility that manufactured those products was in flagrant violations of United States Food and Drug Administration ('FDA') health, safety, and manufacturing regulations. The complaint further alleges that defendants willfully or recklessly concealed these violations from investors, even though the violations put Abbott's infant formula business in dire jeopardy and left the Company exposed to a risk of severe regulatory action, including the recall of its products and closure of the Sturgis facility. Indeed, according to the complaint, defendants received direct warnings, communications, FDA inspection reports, and consumer complaints identifying in detail the safety and regulatory violations that were rampant at the Sturgis facility.
Fulgent Genetics, Inc. (NASDAQ:FLGT)
FLGT Lawsuit on behalf of: investors who purchased March 22, 2019 - August 4, 2022
Lead Plaintiff Deadline : November 21, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/fulgent-genetics-lawsuit-loss-submission-form?prid=32300&wire=1
According to the filed complaint, during the class period, Fulgent Genetics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Fulgent had been conducting medically unnecessary laboratory testing, engaging in improper billing practices in relation to laboratory testing, and providing or receiving remuneration in violation of the Anti-Kickback Statute and Stark Law; (ii) accordingly, Fulgent was likely to become subject to enhanced legal and regulatory scrutiny; (iii) Fulgent's revenues, to the extent they were derived from the foregoing unlawful conduct, were unsustainable; (iv) the foregoing, once revealed, was likely to subject the Company to significant financial and/or reputational harm; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
SOURCE: Levi & Korsinsky, LLP
Get a daily dose of Dallas Sun news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Dallas Sun.
More InformationMURCIA, Spain: Authorities said a nightclub fire over the weekend in the southeastern Spanish city of Murcia killed 13 people ...
SAN FRANCISCO, California: To resolve a pending litigation with the Oregon affiliate of the International Container Terminal Services Inc (ICTSI), ...
PANAMA CITY, Panama: On September 30, the Panama Canal said that due to a drought that has reduced the supply ...
TRIPOLI, Libya: Italy and Libya resumed commercial flights for the first time in ten years on September 30, with flight ...
SAINT GEORGE, Maine: A fire destroyed several waterfront buildings in Maine on September 29, including an art gallery with several ...
JAKARTA, Indonesia - According to Asian diplomats and the Philippines' president, Southeast Asian leaders have decided that Myanmar will not ...
TOKYO, Japan: Tokyo-based startup Tsubame Industries has developed a four-wheeled robot that resembles the "Mobile Suit Gundam" from the popular ...
ISLAMABAD, Pakistan - According to The News, the federal government is considering selling its stake in the Reko Diq project ...
NEW YORK, NEW YORK - U.S. stocks tumbled on Tuesday as interest rates on 10 and 30-year Treasury yields approached ...
DUBLIN, Ireland: The chief medical officer has issued a stark warning regarding the alarming levels of cannabis consumption in Ireland, ...
OAKLAND, California: As their current contract expires and their unions prepare to strike, Kaiser Permanente workers' representatives said, on September ...
FRANKFURT, Germany: Inflation in the eurozone hit a two-year low in September, signaling that the European Central Bank's (ECB) strategy ...